The Expression of HER2/neu in Patients with Lung Cancer and Its Associated Factors

Overview

Journal Clin Respir J

Specialty Pulmonary Medicine

Date 2023 Jan 8

PMID 36617420

Authors

Mohammadreza Lashkarizadeh

Mahdiyeh Lashkarizadeh

Meead Nikian

Maryam Kouhestani Parizi

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Lung cancer is the most common cause of cancer-related death worldwide in both sexes. Evidence suggests the role of genetic factors in lung cancer. Studying of such factors can help understand the cancer prognosis. Overexpression of the human epidermal growth factor receptor-2 (HER2/neu) protein is considered an important prognostic factor in breast cancer, but its role has not been confirmed in lung cancer. Therefore, the present study aimed to investigate the role of its expression in patients with lung cancer.

Materials And Methods: In this cross-sectional study, patients aged >18 years who were referred to Afzalipoor Hospital, Kerman, Iran, from 2016 to 2017, and were diagnosed with lung cancer were enrolled into the study if they had a pathological sample of their cancerous lung. Their demographics were recorded, and the sample was sectioned and stained to measure HER2/neu gene expression according to DAKO instructions using heat-induced antigen retrieval (HIER) enzyme marker.

Results: The samples of 100 patients with lung cancer were evaluated (84% men and 16% women) with a mean age of 61.34 years (standard deviation of 12.51 years). HER2/neu expression was significantly associated with the type of cancer and was highest in adenocarcinoma and zero in small cell carcinoma (P < 0.001), but not with patients' sex, age, smoking status and family history of cancer (P > 0.05).

Conclusion: These results emphasized the overexpression of HER2/neu in different types of lung cancer, which can be used further for therapeutic purposes. The results showed that HER2/neu was overexpressed not only in adenocarcinoma but also in other types, like squamous cell carcinoma. Therefore, all subtypes of non-small cell lung carcinoma should be considered for anti-HER2 therapies, and further research is required for small cell lung carcinoma.

Citing Articles

Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung).

Citarella F, Takada K, Cascetta P, Crucitti P, Petti R, Vincenzi B J Transl Med. 2024; 22(1):714.

PMID: 39085889 PMC: 11293007. DOI: 10.1186/s12967-024-05538-4.

The expression of HER2/neu in patients with lung cancer and its associated factors.

Lashkarizadeh M, Lashkarizadeh M, Nikian M, Kouhestani Parizi M Clin Respir J. 2023; 17(2):90-95.

PMID: 36617420 PMC: 9892694. DOI: 10.1111/crj.13572.

References

Mazieres J, Peters S, Lepage B, Cortot A, Barlesi F, Beau-Faller M . Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31(16):1997-2003. DOI: 10.1200/JCO.2012.45.6095. View

Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K . Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019; 11:943-953. PMC: 6345192. DOI: 10.2147/CMAR.S187317. View

Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L . Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clin Lung Cancer. 2015; 17(5):384-390. DOI: 10.1016/j.cllc.2015.11.004. View

Landi L, Cappuzzo F . HER2 and lung cancer. Expert Rev Anticancer Ther. 2013; 13(10):1219-28. DOI: 10.1586/14737140.2013.846830. View

Robichaux J, Elamin Y, Tan Z, Carter B, Zhang S, Liu S . Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018; 24(5):638-646. PMC: 5964608. DOI: 10.1038/s41591-018-0007-9. View

Dela Cruz C, Tanoue L, Matthay R . Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32(4):605-44. PMC: 3864624. DOI: 10.1016/j.ccm.2011.09.001. View

Iqbal N, Iqbal N . Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014:852748. PMC: 4170925. DOI: 10.1155/2014/852748. View

Li C, Fang R, Sun Y, Han X, Li F, Gao B . Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011; 6(11):e28204. PMC: 3227646. DOI: 10.1371/journal.pone.0028204. View

Feng S, Yang S . The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagn Interv Radiol. 2019; 25(4):270-279. PMC: 6622436. DOI: 10.5152/dir.2019.18458. View

10.

Micke P, Hengstler J, Ros R, Bittinger F, Metz T, Gebhard S . c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer. 2001; 92(4):474-9. DOI: 10.1002/ijc.1229. View

11.

Garrido-Castro A, Felip E . HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Transl Lung Cancer Res. 2015; 2(2):122-7. PMC: 4369854. DOI: 10.3978/j.issn.2218-6751.2013.02.02. View

12.

Liu L, Shao X, Gao W, Bai J, Wang R, Huang P . The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010; 5(12):1922-32. DOI: 10.1097/jto.0b013e3181f26266. View

13.

Lashkarizadeh M, Lashkarizadeh M, Nikian M, Kouhestani Parizi M . The expression of HER2/neu in patients with lung cancer and its associated factors. Clin Respir J. 2023; 17(2):90-95. PMC: 9892694. DOI: 10.1111/crj.13572. View

14.

Arcila M, Chaft J, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M . Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012; 18(18):4910-8. PMC: 3865806. DOI: 10.1158/1078-0432.CCR-12-0912. View

15.

Lemjabbar-Alaoui H, Hassan O, Yang Y, Buchanan P . Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015; 1856(2):189-210. PMC: 4663145. DOI: 10.1016/j.bbcan.2015.08.002. View

16.

Kim H, Shim H, Chung J, Lee Y, Hong Y, Rha S . Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2011; 118(3):729-39. DOI: 10.1002/cncr.26311. View

17.

Takenaka M, Hanagiri T, Shinohara S, Kuwata T, Chikaishi Y, Oka S . The prognostic significance of HER2 overexpression in non-small cell lung cancer. Anticancer Res. 2011; 31(12):4631-6. View

18.

Li C, Sun Y, Fang R, Han X, Luo X, Wang R . Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2011; 7(1):85-9. DOI: 10.1097/JTO.0b013e318234f0a2. View

19.

Pao W, Girard N . New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2):175-80. DOI: 10.1016/S1470-2045(10)70087-5. View

20.

Sperduto P, Yang T, Beal K, Pan H, Brown P, Bangdiwala A . Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2016; 3(6):827-831. PMC: 5824323. DOI: 10.1001/jamaoncol.2016.3834. View